Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1

被引：4
|
作者：
Ma, Jianhui
Liu, Wen
Chung, Heekyung
Izadi, Hooman
DeJong, Petrus
Harismendy, Olivier
Li, Jia
Donate, Fernando
Samatar, Ahmed
Lackner, Mark
Escoubet, Laure
Bunker, Kevin
Kim, Daehwan
Jameson, Nathan
Ozmen, Tugba Yildiran
Jeong, Kangjin
Zhang, Dong
Pan, Wen-An
Mills, Gordon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2153
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2153
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation.
    Wilson, Andrew J.
    Saskowski, Jeanette
    Khabele, Dineo
    CANCER RESEARCH, 2016, 76
  • [32] New Potent and Selective Inhibitor of Pim-1/3 Protein Kinases Sensitizes Human Colon Carcinoma Cells to Doxorubicin
    Moreau, Pascale
    Dezhenkova, Lyubov G.
    Anizon, Fabrice
    Nauton, Lionel
    Thery, Vincent
    Liang, Shuguang
    Kaluzhny, Dmitry N.
    Shtil, Alexander A.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (09) : 1228 - 1236
  • [33] Long noncoding RNA LINC02568 sequesters microRNA-874-3p to facilitate malignancy in breast cancer cells via cyclin E1 overexpression
    Dong, Yi
    Zhang, Lianbo
    Guan, Xin
    Liu, Tao
    Zhou, Limin
    ONCOLOGY RESEARCH, 2021, 29 (04) : 291 - 303
  • [34] MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective non-small cell lung cancer (NSCLC) cells
    Bridges, Kathleen
    Hirai, Hiroshi
    Buser, Carolyn
    Meyn, Raymond E.
    CANCER RESEARCH, 2010, 70
  • [35] Long non-coding RNA ELDR enhances oral cancer growth by promoting ILF3-cyclin E1 signaling
    Sur, Subhayan
    Nakanishi, Hiroshi
    Steele, Robert
    Zhang, Dapeng
    Varvares, Mark A.
    Ray, Ratna B.
    EMBO REPORTS, 2020, 21 (12)
  • [36] miR-576-3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD-L1 and cyclin D1
    Zuo, Ying
    Zheng, Wei
    Tang, Qing
    Liu, Jing
    Wang, Shanshan
    Xin, Chunxia
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01)
  • [37] 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
    Aziz, Diar
    Etemadmoghadam, Dariush
    Caldon, C. Elizabeth
    Au-Yeung, George
    Deng, Niantao
    Hutchinson, Ryan
    Bowtell, David
    Waring, Paul
    GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 327 - 336
  • [38] BRCA1 Expression Is Epigenetically Repressed in Sporadic Ovarian Cancer Cells by Overexpression of C-Terminal Binding Protein 2
    May, Taymaa
    Yang, Junzheng
    Shoni, Melina
    Liu, Shubai
    He, Housheng
    Gali, Reddy
    Ng, Shu-Kay
    Crum, Christopher
    Berkowitz, Ross S.
    Ng, Shu-Wing
    NEOPLASIA, 2013, 15 (06): : 600 - +
  • [39] BRCA1 expression is suppressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein-2
    May, T.
    Yang, J.
    Shoni, M.
    Liu, S.
    He, H.
    Gali, R.
    Berkowitz, R.
    Ng, S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S142 - S142
  • [40] IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
    Au-Yeung, George
    Bressel, Mathias
    Prall, Owen
    Surace, Daniela
    Andrews, John
    Mongta, Sally
    Lee, Yeh Chen
    Gao, Bo
    Meniawy, Tarek
    Baron-Hay, Sally E.
    Black, Allison Jane
    Kichenadasse, Ganessan
    Ananda, Sumitra
    Fox, Peter
    Bowtell, David
    Mileshkin, Linda R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345